Neurology® Podcast December 2024 Recall: Topics in Autoimmune Neurology
Dec 1, 2024
Join neurologists John Pluvinage, Andrew McKeon, Martin Tichler, Jolt Elesch, and Marius Ringelstein in a fascinating discussion on autoimmune neurology. Pluvinage dives into anti-CD320 antibodies and their clinical significance. McKeon reveals insights about paraneoplastic CAMKV autoimmune encephalitis. Tichler highlights long-term outcomes in anti-NMDAR encephalitis patients. Elesch examines mortality rates in AQP4 antibody-positive neuromyelitis optica, while Ringelstein evaluates the efficacy of Eculizumab in clinical settings. Tune in for cutting-edge insights in neurology!
AI Snips
Chapters
Transcript
Episode notes
Long Recovery after Anti-NMDAR Encephalitis
- Anti-NMDAR encephalitis causes severe illness but patients show prolonged, slow recovery over years.
- Major improvements occur in six months, yet functional gains continue up to three years, emphasizing long-term rehabilitation.
Engage Caregivers Early and Honestly
- Support caregivers by educating them on recovery phases and setting realistic expectations.
- Encourage patience and emphasize the monophasic nature with potential for medication taper and functional gains.
HSV Often Triggers Anti-NMDAR Encephalitis
- About 10% of anti-NMDAR encephalitis is preceded by HSV-1 encephalitis.
- These patients tend to have worse outcomes due to HSV-related damage, underscoring the need for autoimmune testing post-HSV encephalitis.